Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma.
Surveillance de la santé et des maladies
Téléchargement 4.28 MoPeer reviewed scientific article
Anglais
Auteurs
Timothy Devos [3]; Quentin Van Thillo [4]; Veerle Compernolle [5]; Najdovski, Tomé [6]; Marta Romano [7]; Nicolas Dauby [8]; Laurent Jadot [9]; Mathias Leys [10]; Evelyne Maillart [11]; Sarah Loof [12]; Lucie Seyler [13]; Martial Moonen [14]; Moutschen, Michel [15]; Niels Van Regenmortel [16]; Ariën, Kevin K [17]; Cyril Barbezange [18]; Albrecht Betrains [19]; Mutien Garigliany [20]; Matthias M Engelen [21]; Iwein Gyselinck [22]; Piet Maes [23]; Alexander Schauwvlieghe [24]; Laurens Liesenborghs [25]; Ann Belmans [26]; Peter Verhamme [27]; Geert Meyfroidt [28]Mots-clés
Résumé:
BACKGROUND: Several randomised clinical trials have studied convalescent plasma (CP) for COVID-19 using different protocols, with different SARS-CoV-2 neutralising-antibody-titres, at different time-points and severities of illness.
METHODS: In the prospective multicentre DAWN-plasma trial, adult patients hospitalised with COVID-19 were randomised to 4 units of open-label convalescent plasma combined with standard of care (intervention group) or standard of care alone (control group). Plasma from donors with neutralising-antibody-titres (NT50) ≥⅓20 was the product of choice for the stu…